Physician profile
Grace Lee
NPI 1932580743
$2,590.39
in general payments reported to CMS, 2019-2025
26 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.95 · 2021: $155 · 2022: $767 · 2023: $695 · 2024: $654 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,649.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $493.79 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $414.46 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $275.01 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $235.09 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Medtronic, INC. | $159.47 | 2024 | Interstim |
| Esperion Therapeutics, INC. | $124.92 | 2024 | Nexlizet, Nexletol |
| Amarin Pharma, INC. | $100.34 | 2021-2022 | |
| Pfizer INC. | $88.04 | 2023-2025 | |
| Amgen INC. | $82.07 | 2023-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.48 | 2022-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $76.24 | 2022 | |
| Boston Scientific Corporation | $72.87 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.63 | 2022-2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $44.28 | 2023 | Quviviq |
| Exact Sciences Corporation | $39.74 | 2023 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $33.75 | 2022 | |
| Erbe USA INC | $30.00 | 2025 | Cryo2 |
| Phadia US INC. | $24.24 | 2024 | Immunocap |
| Takeda Pharmaceuticals U.S.A., INC. | $23.98 | 2023 | Trintellix |
| Abbott Laboratories | $23.30 | 2024 | Proclaim |
| Sanofi Pasteur INC. | $22.15 | 2022 | |
| Axsome Therapeutics, INC. | $19.99 | 2023 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $18.94 | 2024 | |
| Philips North America LLC | $17.91 | 2024 | (Ak6) Vest Therapy |
| Abbvie INC. | $14.57 | 2022 | |
| Bausch Health US, LLC | $14.13 | 2024 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.